Study of clinical characteristics in patients with gp210 antibody-positive primary biliary cholangitis.
10.3760/cma.j.cn501113-20210501-00216
- VernacularTitle:抗gp210抗体阳性原发性胆汁性胆管炎患者临床特点研究
- Author:
Chun Yang HUANG
1
;
Yan Min LIU
1
;
Hui LIU
2
;
Bin XU
1
;
Hui Ping YAN
3
;
Hai Ping ZHANG
4
;
Hui Yu LIAO
1
;
Xiao Dan ZHANG
1
;
Juan ZHAO
1
;
Wen Juan LI
1
;
Zhong Ping DUAN
5
Author Information
1. Department of Liver Disease Center, Beijing You'an Hospital Affiliated to Capital Medical University, Beijing 100069, China.
2. Department of Pathology, Beijing You'an Hospital Affiliated to Capital Medical University, Beijing 100069, China.
3. Department of Liver Disease Center, Beijing You'an Hospital Affiliated to Capital Medical University, Beijing 100069, China Capital Medical University Department of Laboratory Medicine, Affiliated Beijing You'an Hospital, Beijing 100069, China.
4. Capital Medical University Department of Laboratory Medicine, Affiliated Beijing You'an Hospital, Beijing 100069, China.
5. Department of Critical Hepatology, Beijing You'an Hospital Affiliated to Capital Medical University, Beijing 100069, China.
- Publication Type:Journal Article
- MeSH:
Aspartate Aminotransferases;
Autoantibodies;
Female;
Humans;
Liver Cirrhosis, Biliary/diagnosis*;
Liver Failure;
Male;
Retrospective Studies
- From:
Chinese Journal of Hepatology
2022;30(4):419-425
- CountryChina
- Language:Chinese
-
Abstract:
Objective: To analyze the clinical characteristics and prognostic value of liver function in a large samples of patients with anti-glycoprotein 210 (gp210 antibody) positive primary biliary cholangitis (PBC). Methods: A retrospective study was performed on 931 PBC cases in Beijing You'an Hospital affiliated to Capital Medical University from 2010 to 2019. According to the detection of gp210 antibody, 318 cases were divided into gp210 antibody positive group (positive group) and 613 cases were divided into gp210 antibody negative group (negative group). The differences in demographic, medical history, clinical indicators, B-ultrasound and pathological indicators as well as the histopathological basis were compared between the two groups. SPSS 16.0 software was used for statistical analysis. Measurement data were analyzed by t-test or rank sum test, and enumeration data by χ2 test. Multivariate analysis was used for logistic test, and and survival analysis was used for prognosis. Results: The positive and the negative groups were compared. The ratio of male to female was significantly higher in positive than negative group (1:5.35 vs. 1:9.73, P＜0.05), and the difference was statistically significant. The proportion of hormone use in history of past diagnosed and treated was higher in positive than negative group (12.9% vs. 3.47%, P＜0.05), and the difference was statistically significant. The detection of biochemical indexes such as alanine aminotransferase (ALT), aspartate aminotransferase (AST), total bilirubin (TBIL), alkaline phosphatase (ALP), glutamyl transpeptidase (GGT) were higher in positive than the negative group (51.1 U/L vs. 41.1 U/L, 62.6 U/L vs. 49.6 U/L, 24.1 μmol/L vs. 17.9 μmol/L, 228.3 U/L vs. 169.6 U/L, 203.9 U/L vs. 147.6 U/L), (P＜0.05), and the differences were statistically significant. Antinuclear antibody (ANA)-positive rate, high titer ratio and immunoglobulin G (IgG) levels were higher in positive than negative group (95.2% vs. 81.6%, 69.7% vs. 48.8%, 17.2 g/L vs. 16.2 g/L), (P＜0.05), and the differences were statistically significant. The incidence of liver failure was higher in positive than negative group (P＜0.05). CK7 and inflammation score were higher in positive group than negative group in liver histopathological observations (0.83±0.53 vs. 0.28±0.47; 1.06±0.39 vs. 0.54±0.65), (P＜0.05), and the differences were statistically significant. Conclusion: The illness condition of patients with gp210 antibody positive PBC is more severe than patients with gp210 antibody negative PBC, and the incidence of liver failure is significantly increased. Cholangiocytes may be the histopathological basis of the clinical characteristics of gp210 antibody positive PBC patients.
